Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial

Peter Schmid; Jacinta Abraham; Stephen Chan; Duncan Wheatley; Adrian Murray Brunt; Gia Nemsadze; Richard D. Baird; Winnie Yeo; Peter Hall; Timothy Perren; Robert C. Stein; László Mangel; Jean-­Marc Ferrero; Melissa Phillips; John Conibear; Javier Cortés; Andrew Foxley; Elza C. de Bruin; Robert McEwen; Daniel Stetson; Brian Dougherty; Shah‐Jalal Sarker; Aaron Prendergast; Max McLaughlin-Callan; Matthew Burgess; Cheryl Lawrence; Hayley Cartwright; Kelly Mousa; Nicholas C. Turner

doi:10.1200/jco.19.00368

Abstract

Addition of the AKT inhibitor capivasertib to first-line paclitaxel therapy for TNBC resulted in significantly longer PFS and OS. Benefits were more pronounced in patients with PIK3CA/AKT1/PTEN-altered tumors. Capivasertib warrants further investigation for treatment of TNBC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Schmid et al. (2019) studied this question.

synapsesocial.com/papers/69d9b4655e5bcb4e3b837b2a https://doi.org/10.1200/jco.19.00368

View Full Paper

Ask AI

Bookmark

Share

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial

Abstract

Discussion

Cite This Study

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Journal of Clinical Oncology

Keep reading

More related papers

More from Journal of Clinical Oncology